Exabis Library
Welcome to the e-CCO Library!
P495: Does drug level monitoring help us to understand the mechanism behind the superiority of combo therapy in inflammatory bowel diseases?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P495: Intensified infliximab rescue therapy for acute severe ulcerative colitis does not improve long term colectomy-free survival
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P495: Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P495: Spacing the administration interval of anti-TNF agents: a valid strategy for patients with inflammatory bowel disease?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P495: The interplay of biopsychosocial factors and quality of life in Inflammatory Bowel Diseases: a network analysis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P495: Vedolizumab trough concentrations and histological remission in Ulcerative Colitis: Results from the LOVE-UC study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P496 Feasibility and safety of single incision laparoscopic surgery for patients with complex Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P496: Adalimumab treatment reduces extraintestinal manifestations in patients with moderate-to-severe Crohn’s disease: a pooled analysis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P496: Antenatal thiopurine exposure in women with IBD is associated with intrahepatic cholestasis of pregnancy
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P496: Efficacy and safety of elective switching of inflammatory bowel disease patients from intravenous to subcutaneous infliximab (IFX): a multi-centre cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P496: Efficacy and safety of ustekinumab for chronic antibiotic refractory pouchitis: A Belgian open-label multicentre pilot study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P496: Impact of ulcerative colitis on costs, work productivity and quality of life: a prospective study in a single referral centre
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P496: Real-world outcomes of vedolizumab for inflammatory bowel disease post liver transplantation
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P496: Successful dose de-escalation to adalimumab 40mg every three weeks in patients with Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P497 Is mucosal healing sufficient paramater for anti-TNF discontinuation?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P497: Clinical features and outcomes of tuberculosis in inflammatory bowel disease patients treated with anti-TNF therapy as compared with the general population
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P497: Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P497: IL-33/ST2 levels and gut microbiota characterisation can predict mucosal response to anti-TNF therapy in ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P497: Impacts of mucosal healing on clinical outcomes in patients with refractory ulcerative colitis on tacrolimus or biologics
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P497: Injection site reactions and injection site pain for the adalimumab biosimilar ABP 501: Results from two double-blind, randomised, controlled studies
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM